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ABSTRACT

ARTICLE HISTORY

Uveal melanoma (UM) represents an aggressive type of cancer and currently, there is no effective treatment for this metastatic disease. In the last years, histone deacetylase inhibitors (HDACIs) have been
studied as a possible therapeutic treatment for UM, alone or in association with other chemotherapeutic
agents. Here we synthesised a series of new HDACIs based on the SAHA scaffold bearing an (arylidene)aminoxy moiety. Their HDAC inhibitory activity was evaluated on isolated human HDAC1, 3, 6, and 8 by
fluorometric assay and their binding mode in the catalytic site of HDACs was studied by molecular docking. The most promising hit was the quinoline derivative VS13, a nanomolar inhibitor of HDAC6, which
exhibited a good antiproliferative effect on UM cell lines at micromolar concentration and a capability to
modify the mRNA levels of HDAC target genes similar to that of SAHA.
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1. Introduction
Uveal melanoma (UM) is a highly aggressive form of melanoma
and is the most common primary intraocular tumour in adults.
The traditional clinical treatment of patients with UM is the enucleation of the affected eye or, to preserve the vision or the globe,
other clinical options are radiotherapy, photodynamic therapy,
and systemic chemotherapy1. About 50% of the patients have
strong tendency to develop lethal metastasis, principally to the
liver (89%), that are usually identified 2–5 years after treatment of
the primary tumour and are poorly sensitive to chemotherapy.
Thus, the prognosis of these patients becomes poor with a
median survival of 2–18 months. UM can be grouped in two
classes on the basis of their gene expression profile: Class I
tumours with very low metastatic risk and Class II with a high risk
of metastasis2. In the last 10 years metastatic UM has been
studied at the genetic and molecular levels to discover effective
target therapies. Epigenetic alterations, such as changes in DNA
methylation and histone acetylation status, are involved in tumour
progression3.
In the past years, a group of enzymes involved in the epigenetic regulation of gene expression, histone deacetylases (HDACs),
have generated increasing interest as potential therapeutic targets
for UM4–6. HDACs remove the acetyl groups from histone lysine
residues from diverse protein targets, resulting in a condensed
chromatin structure that downregulates gene expression, also of
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tumour suppressor genes7. The status of histone acetylation
depends on the balance between histone acetylation and deacetylation, induced by histone acetyltransferases (HATs), and HDACs,
respectively. Increasing evidence suggests that the alteration of
HAT/HDAC activity is present in cancer8. In mammalians, 18 different HDACs have been identified and divided into four classes
(Class I, Class II, Class III, and Class IV) based on their sequence
homology to yeast proteins domain organisation and subcellular
localisation. Class I (subtypes 1,2,3,8), II (subtypes 4,5,6,7,9,10), and
IV (subtype 11)9 HDACs are zinc-dependent enzymes, while Class
III HDACs (SIRTs 1–7) require the cofactor NADþ to express their
activity. Class I can generally be detected in the nucleus and is
ubiquitously expressed.
HDACs are overexpressed in a wide range of diseases including
tumours and consequently become attractive targets for the
development of drugs for cancer treatment10–12.
HDAC inhibitors (HDACIs) interfere with the deacetylation process mediated by HDACs with an increase of histone acetylation.
HDACIs induce cancer cell death through several pathways: apoptosis, differentiation, cell cycle arrest, and suppression of cell
migration. In UM HDACIs induce morphological differentiation and
cell-cycle arrest and inhibit the growth of UM tumour in vivo5,13,14.
The first HDAC inhibitor approved by the FDA, in 2006, was
Vorinostat (SAHA) for the treatment of cutaneous T-cell lymphoma
(CTCL)15. To date other three HDAC inhibitors have been
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Figure 1. Representative compounds of the different structural classes of HDAC inhibitors. Chemical structures of clinically approved drugs are highlighted in box.

approved by FDA: Romidepsin (FK228)16 in 2009, Belinostat
(PXD101)17 in 2014 for the treatment of CTLC or Peripheral T-cell
lymphoma (PTCL), and Panobinostat (LBH589)18 in 2015 for
Multiple myeloma and CTCL. Chidamide (HBI-8000) has been
approved by the Chinese FDA for relapsed or refractory PTCL in
201519 (Figure 1). In vitro studies with some of these HDACIs have
shown a shift of the gene expression profile from Class II (high
metastatic risk) to a Class I (low metastatic risk) in UM cell cultures5. Moreover, it has been recognised that HDAC inhibitors
such as Vorinostat (SAHA) and Panobinostat (LBH589), may be
useful in adjuvant therapy in patients with high-risk Class II UM
playing a role in preventing the progression of micrometastatic disease13.
Several structural classes of HDAC inhibitors, both natural and
synthetic, have been reported in the literature such as hydroxamates, carboxylates, benzamides, and cyclic peptides (Figure 1). A
variety of derivatives of each class have been synthesised and
characterised20. All classes of HDAC inhibitors share a common
pharmacophore model, which consists of a CAP group, a connection unit (CU), a linker and a zinc-binding group (ZBG) that is

Figure 2. Pharmacophore model of the newly synthesised compounds.

mostly represented by a hydroxamic acid (Figure 2). Modifications
of these four structural parts such as the CAP group, the linker, or
the ZBG, have become important strategies that have led to the
development of a large number of HDACIs21.
As part of our ongoing efforts in identifying new HDAC inhibitors potentially active in UM, we decided to develop a series of
hydroxamates based on SAHA scaffold. The choice of SAHA structure as a starting point of our study was based on two considerations: SAHA is an anticancer drug in clinical use and, moreover, its
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activity on UM has been already proved by Landreville et al.
through an in vitro study on UM cell lines13.
In this context, we envisioned developing new HDAC SAHAbased inhibitors of general structure A (Figure 2) in which the
amidic group of SAHA is replaced by a different connection unit
(CU). In fact, in the synthesised compounds (1a–c, 2a–f, 3a–c and
4a–e, Scheme 1) the linker and the hydrophobic CAP group (R)
are connected via an oxime ether moiety (C ¼ N–O–) possessing a
sp2-hybridization, analogously to other CU used in many HDAC
inhibitors22.
Furthermore, since it is widely accepted that the CAP group
plays an important role in the HDAC inhibition profile, we have
synthesised new derivatives in which the CAP group was changed
from a phenyl group of SAHA into a more bulky aromatic moiety.
We have also investigated the influence of the linker length on
HDAC inhibition activity synthesising compounds with two or four
carbon atoms in the linear alkyl chain (Figure 2).
In the present paper, we report the synthesis and HDAC inhibitory activity of both hydroxamic compounds of type A
(R2¼NH–OH, 1a–c, 2a–f) and their corresponding carboxylic acid
analogues (R2¼OH, 3a–c, 4a–e). The HDAC inhibitory activity of
the new compounds was first evaluated against HeLa cell nuclear
extract containing a mixture of Class I HDACs. Then, with the aim
to deeply investigate the biological properties of the four most
promising hydroxamic derivatives, we performed in vitro assays on
isolated Class I enzymes (HDACs 1,3,8) and Class II HDAC6.
Considering the expression of histone deacetylases in UM23 and
the potential therapeutic role of HDACIs in this tumour5, the same
compounds were selected for further tests on UM cell lines.
Finally, docking studies were performed to investigate their binding mode.

2. Results and discussion
2.1. Chemistry
The synthesis of the target compounds is outlined in Scheme 1.
Ethyl esters 6a–c were obtained by Michael–type reaction of
oximes 5a–f with ethyl acrylate, while ethyl esters 7a–f were
obtained by reaction of the opportune oximes 5a–f with the ethyl
ester of 5-bromovaleric acid using Cs2CO3 as base. The hydroxamic acids 1a–c (n ¼ 1) and 2a–f (n ¼ 2) were directly obtained
from the ethyl esters 6a–c and 7a–f, respectively, by treatment

with aqueous hydroxylamine in basic conditions. The carboxylic
acids 3a–c (n ¼ 1) and 4a–d (n ¼ 2) were obtained by saponification with 2 N KOH in ethanol of the ethyl esters 6a–c and 7a–f.
2.2. In vitro HDACs inhibition assays
The hydroxamic acids 1a–c, 2a–f and carboxylic acids 3a–c, 4a––e
synthesised in this study were preliminarily tested on a HeLa
nuclear extract containing a mixture of HDACs, by using a commercially available HDAC assay kit (BIOMOL). Inhibitory data
expressed as IC50 values are reported in Table 1. SAHA and
Trichostatin A (TSA) were used as positive controls.
The results of this preliminary screening, reported in Table 1,
showed that compounds bearing a hydroxamic moiety as ZBG
possess HDAC inhibitory activity while the carboxylic function as
ZBG is detrimental to HDAC inhibition. The length of the linker
influences the HDAC inhibitory activity and a 4-carbon linear aliphatic chain appears nearly optimal: IC50 values of compounds
with n ¼ 1 are in the micromolar range while the IC50 values of
compounds with n ¼ 2 are in the nanomolar range. Among the
hydroxamic acids with n ¼ 2, those having bulkier CAP groups
exhibited superior activity than monoacrylic derivatives. The most
potent compounds, 2b (SN2), 2c (LD10), 2e (VS16), and 2f
(VS13), as shown in Table 1, resulted 3- to 5-folds more potent
than SAHA and were selected for a deeper biological evaluation.
The selected hydroxamates (SN2, VS16, LD10, and VS13) were
tested for their inhibitory activity towards four human isolated
HDACs: HDACs 1, 3, and 8 (Class I HDACs) and HDAC 6 (a Class II
HDAC) to investigate how the different CAP groups could influence the HDAC activity24. In particular, HDAC6, which was not present in the HeLa nuclear extract used for the preliminary tests, is
considered an important target in cancer therapy25–27. SAHA, entinostat, and tubastatin A were used as positive controls. As summarised in Table 2, all compounds (except LD10 at HDAC1) were
able to inhibit HDAC1, HDAC3, and HDAC6 in the nanomolar
range while they were less efficient against HDAC8, displaying
IC50 values in the low micromolar range. Moreover, compounds
SN2, VS16, and LD10 resulted in more active on HDAC3 than on
the other isoforms. For example, SN2 and VS16 had lower IC50
values (58 nM and 43 nM, respectively) for HDAC3 than those for
HDAC1 (698 nM and 593 nM, respectively), or for HDAC6 (316 nM
and 406 nM, respectively). Dose-response curves are illustrated in
Supplementary Figure S1.

Scheme 1. Synthesis of the hydroxamic acids 1a-c, 2a-f and carboxylic acids 3a-c, 4a-e.
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Table 1. HDACs inhibitory activity of the newly synthesised compounds 1a–c,
2a–f, 3a–c, 4a–e.

R

Compd.

R1

R2

n

IC50 on Hela
extract (mM)a

1a
3a

H3CS

H
H

NHOH
OH

1
1

NTb
>100

2a
4a

H3CS

H
H

NHOH
OH

2
2

2.880
>100

1b
3b

H
H

NHOH
OH

1
1

43.2
>100

2b (SN2)
4b

H
H

NHOH
OH

2
2

0.056
>100

1c
3c

H
H

NHOH
OH

1
1

3.346
>100

2c (LD10)
4c

H
H

NHOH
OH

2
2

0.096
>100

2d
4d

H
H

NHOH
OH

2
2

4.6
>100

2e (VS16)
4e

Me
Me

NHOH
OH

2
2

0.053
>100

2f (VS13)

H

NHOH

2

0.054

SAHA
TSA
a

0.280
0.037

Values are means of at least three experiments, SD values are <20% of the
mean; bnot tested.

Among the four selected compounds, the most active on all
the HDACs considered in this work was the quinoline derivative
VS13 that showed a stronger effect on HDAC6 than on the other
isoforms. In particular, VS13 was active at 10 nM on HDAC6, only
7 times less active than SAHA and 900 times more selective for
HDAC6 over HDAC8.
These compounds were chosen for further evaluation on UM
cell lines and docking studies were carried out to explain their different selectivity profile.
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2.3. Docking studies
Compounds LD10, VS13, SN2, and VS16 were docked in HDAC1,
HDAC3, HDAC6, and HDAC8.
The superposition between the docked-pose of two investigated compounds LD10 and VS13 and the PDB structures
(human HDACs in complex with hydroxamate inhibitors28) showed
a quite different disposition of both ligands in the HDACs binding
site. Specifically, the CAP group of these inhibitors occupies a
region between loop3 and loop4 of HDACs, while that of the crystallised hydroxamate inhibitors28 is allocated around loop1, loop2,
and loop4 (Figure 3).
In the HDAC-inhibitor crystal complexes, the region filled by
the CAP of our inhibitors is frequently (but not constantly) occupied by water molecules which engaged hydrogen bonds with
the catalytic histidine. The different pose displayed by compounds
LD10 and VS13 could be related to the substitution of the typical
amidic connection unit, present in the HDAC inhibitors, with the
methyloximino moiety. This group seems to modify the flexibility
of the inhibitors and, consequently, the CAP fitting with the protein surface.
The comparison of the four HDAC subtypes highlighted that
the core structure of the catalytic domain is well conserved
(Figure 4(a–d)). The only exception was the different orientation
displayed by Phe152, in HDAC8, with respect to Phe150 (HDAC1),
Phe144 (HDAC3), and Phe620 (HDAC6) (Figure 4(a–d), Figure 5).
Moreover, analysis of loops3 and 4 displayed a detectable
sequence and conformational variability among the four HDAC
isozymes (Figures 4 and 5).
The major differences were found in HDAC8 where both loops
possess not conserved residues (Figure 5; alignment generated
using PRALINE29) which influence the binding site surface and the
backbone shape. Precisely, loop4 of HDAC8 opens the binding
cavity outside, with respect to the arrangement of the same loop
in HDAC1 and HDAC3 (see also the surface in Figure 4). On the
contrary, the arrangement of loop3 in HDAC8 (as in HDAC1)
shrinks the binding channel.
GOLD calculation showed that all ligands have a zinc-coordinated pose in the HDACs binding site.
Regarding the CAP group orientation, the differences between
loop3 and 4 regions among the HDAC subtypes can induce a different pose of the studied ligands. While in HDAC3 and 6 the CAP
group of LD10 and VS13 was oriented towards loop3, in HDAC8
it pointed towards loop4 (Figure 4). A similar trend to HDAC8 was
registered in HDAC1 for LD10 inhibitor.
In HDAC8, both ligands LD10 and VS13 coordinated the catalytic zinc and established one polar interaction with the His143 of
the second binding shell (Figure 4(d)).
In HDAC1 core, the hydroxamic moiety of both inhibitors
established two hydrogen bonds with His141 and Tyr303. In addition, the aromatic portion of VS13 was orientated towards loop3
thanks to a weak polar interaction of the quinoline nitrogen with
the backbone (dH-N ¼ 2.8 Å) (Figure 4(a)).
In HDAC3, the LD10 and VS13 hydroxamate group was stabilised through two hydrogen interactions with His135 and Tyr298.
Both aromatic CAP groups pointed towards loop3, in particular,
the quinoline nitrogen of VS13 engaged a strong hydrogen bond
with the loop3’s backbone (Figure 4(b)).
A similar ligands pose was calculated in HDAC6 where the
hydroxamate group was further stabilised by the His610 of the
second catalytic shell (Figure 4(c)).
Therefore, docking results showed a progressive increment
from HDAC8 to HDAC1, HDAC3 and HDAC6 in the polar interactions which strengthened the stabilisation of the inhibitors in the
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Table 2. HDACs inhibitory selectivity profile of selected hydroxamic acids, SAHA, entinostat and tubastatin A.
IC50 (mM)a
Compd.

Chemical structure

HDAC1

HDAC3

SN2

0.698

0.058

HDAC6
0.316

8.206

VS16

0.593

0.043

0.406

13.680

LD10

6.043

0.594

0.836

>30

VS13

0.137

0.040

0.010

9.29

SAHA
Entinostat
Tuastatin A

0.007
1.480b
2.866

0.0014
0.790b
0.766

0.0014
>30b
0.015

HDAC8

0.495
>30b
2.341

Compounds were tested in duplicate in a 10-point dose curve with 3-fold serial dilution starting from 30 lM. In the case of SAHA a 15-point dose curve on HDACs
3 and 6 was performed.
See ref.34.

a

b

Figure 3. Superposition of hydroxamate inhibitors co-crystallised in human
HDACs (light grey coloured) and docked-pose of inhibitors LD10 and VS13 (salmon and green coloured, respectively). For clarity, inhibitor poses extracted from
different subtypes are shown in HDAC6 binding site.

binding site and promoted the zinc coordination. Analysing the
VS13 binding pose, it can be hypothesised that a nitrogen atom
in the aromatic CAP ring allows better interaction with loop3 and,
therefore, enhances the inhibitory activity.

Moreover, the computational analysis of compounds SN2 and
VS16 showed that both ligands are similarly located in the four
HDAC binding channel subtypes (Figure 6). The biphenyl CAP of
these ligands is longer than the one present in LD10 and VS13
and it linearly crossed the outer binding regions between loop3
and 4.
As previously mentioned, the loop3 of HDAC8 shrinked the
outer binding channel. This conformation pushed the CAP of SN2
and VS16 inhibitors deeply (more than 2 Å) towards the catalytic
core. This scrunched conformation caused a detrimental folding of
the spacer and allowed only one polar interaction with second
catalytic shell residues.
In the other HDAC subtypes, all SN2 and VS16 poses were
quite superposed. In the outer portion of the binding site, the
biphenyl CAP was located close to loop3 (in a ranking
HDAC3 > HDAC1 > HDAC6) while, in the inner binding pocket, the
number of hydrogen bonds increased from one in HDAC8 to two
in HDAC6 and HDAC1, and finally three in HDAC3 (not shown for
clarity in Figure 6).
For all investigated ligands (LD10, VS13, SN2 and VS16) the
computational study showed tiny differences in the ligand-binding
poses, principally due to the sequence and shape variations of
loops3 and 4 among the four HDAC subtypes.
However, the slight differences of the ligand-binding mode are
crucial to strengthen or decrease the inhibitor interactions and
consequently binding affinity30.
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Figure 4. Docking of LD10 (salmon) and VS13 (green) in (a) HDAC1; (b) HDAC3; (c) HDAC6, and (d) HDAC8. Proper hydrogen bonds are highlighted in cyan.

2.4. Activity on human UM cell lines in vitro
The anti-proliferative effects of the most promising HDAC inhibitors, VS16, VS13, SN2, and LD10 were evaluated on human UM
cell lines (92.1 and Mel270) and SAHA was used as a positive control. First, we assessed by MTT assay the cell viability after a 72 h
treatment at different concentrations. Figure 7 and Supplementary
Figure S2 show that compounds VS16, VS13, and SN2 have a
stronger effect on 92.1 and Mel270 cell viability than SAHA and
LD10. Similar results were found for ovarian carcinoma cell line
A2780 and to a lesser extent for SKOV3 (Supplementary
Figure S2).
We then investigated whether this anti-proliferative effect was
due to the blockade in the G0/G1 phase of the cell cycle, as
expected for SAHA31. Flow cytometry analysis of cell cycle distribution in 92.1 and Mel270 cells after treatment with the different
compounds or control DMSO, indeed showed that VS16, VS13,
SN2, and SAHA efficiently block the cell cycle at the G0/G1 phase
(Figure 8 and Supplementary Figure S3) while LD10 behaved like
the control DMSO.

Finally, we determined if the treatment of UM cells 92.1 and
Mel270 with our compounds could modify the mRNA levels of
HDAC target genes. We chose genes both down-regulated
(RAD54L, RAD51) and up-regulated (CLU, DHRS2, and CDKN1A) by
HDAC inhibitors in cancer cells32,33. As shown in Figure 9 and
Supplementary Figure S4, VS13 induced a pattern of gene modulation, which overlapped that of SAHA. Of note, VS13 shares with
SAHA the high activity on HDAC6 (see Table 2), thus supporting
the hypothesis that these modulatory effects on genes could be
mainly mediated by HDAC6 inhibition on which the other compounds have a lower effect.

3. Conclusions
UM represents an aggressive type of cancer and currently, there is
no effective treatment for metastatic UM. This cancer form is characterised by an overexpression of HDACs and HDAC inhibitors
have been shown to inhibit the growth of UM in vivo and in vitro.
In this study, we synthesised a series of HDACIs based on SAHA
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scaffold bearing an (arylidene)aminoxy moiety. All new compounds were tested first on HeLa nuclear extract to evaluate if
the chemical modification of the SAHA structure maintained the
HDAC inhibitory activity. Among all the synthesised hydroxamates
we tested the most active ones on isolated enzymes, HDAC1, 3, 6,
and 8. The best inhibitory results were obtained with compound

Figure 5. Sequence alignment of loop3 and loop4 regions of HDAC1, 3, 6, and 8.
At bottom, superposition of aligned loop3 and loop4 crystal structures of the
four HDAC subtypes (HDAC1, HADC3, HDAC6, and HDAC8 are magenta, salmon,
grey, and purple coloured, respectively).

VS13, bearing a quinoline as the CAP group, which showed a
nanomolar affinity for HDAC6 (IC50¼10 nM) and a 1000-fold selectivity over HDAC8. On these four hydroxamic acid derivatives docking studies were performed to explain their binding mode and
the interaction inside the HDAC1, 3, 6, and 8 active sites. In particular, the nitrogen of the quinoline ring was shown to play an
important role by forming a strong hydrogen bond with the backbone of loop3 present in HDAC6 catalytic site. The effect of HDAC

Figure 7. MTT. In vitro cytotoxicity at the 72 h time point of the different compounds in human UM cell lines 92.1 and Mel270, as assessed by the MTT cell viability assay. Data are expressed as percent of control with the DMSO solvent,
which was used at the same amount present in the highest compound concentration. Error bars represent SD of quadruplicates. One representative experiment
is shown.

Figure 6. Docking poses of inhibitors SN2 and VS16. The colour code is protein dependent: the complex of both inhibitors in HDAC1, HADC3, HDAC6 and HDAC8 are
magenta, salmon, grey, and purple coloured, respectively. On the left are highlighted the hydrogen bonds engaged by both compounds with second shell catalytic residues of HDAC3.
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Figure 8. Influence of the different compounds and DMSO solvent control on cell cycle distribution in UM 92.1 and Mel270 cells. The cells were treated with 10 mM
compound for 48 h and cell cycle distribution was analysed by flow cytometry after fixation and staining with PI. The percentage of cells in each category is indicated.
One representative experiment is shown.

inhibition in living cells was evaluated by testing the most promising compounds on human UM cell lines, 92.1 and Mel270, in comparison with SAHA. VS13 showed a strong antiproliferative
activity by MTT assay and the ability to efficiently block the cell
cycle at the G0/G1 phase, similarly to SAHA. Finally, we determined if treatment with these compounds could modify the
mRNA levels of HDAC target genes in UM cells and VS13 induced
a pattern of gene modulation which overlapped that of SAHA.
Considering the particular activity of VS13 on HDAC6, these
results support the hypothesis that the modulatory effects on
genes could be mainly mediated by HDAC6 inhibition. However,
additional studies will be necessary to shed light on the mechanism involved in the antitumor activity of HDACIs in this aggressive
type of cancer.

4. Experimental section

Figure 9. Modulation of RAD54L, RAD51 and CLU mRNA expression by the different compounds in UM cells 92.1 and Mel270. Cells were treated for 48 h with
10 mM compound or the corresponding amount of DMSO. Data, normalised to
GAPDH housekeeping gene, are expressed as fold change relative to the DMSO
control. Error bars represent SD of triplicates. One representative experiment
is shown.

4.1. Chemistry

4.2. General procedure for the synthesis of oximes 5a–c, e, f

Analytical grade reagents and solvents were purchased from
Sigma-Aldrich (St. Louis, MO), and were used as supplied. Melting
€fler hot-stage apparatus and are
points were determined on a Ko
uncorrected. 1H and 13C NMR spectra were recorded on a Bruker
Avance III HD 400 MHz spectrometer (F€allander, Switzerland) and
on a Varian Gemini-200 MHz spectrometer. Chemical shifts (d) are
reported in parts per million and coupling constants (J) are
reported in hertz (Hz). 13C NMR spectra were fully decoupled. The
following abbreviations were used to explain multiplicities: singlet
(s), doublet (d), triplet (t), double doublet (dd), broad (br), and
multiplet (m). Chromatographic separations were performed on
silica gel columns by flash column chromatography (Kieselgel 40,
0.040–0.063 mm, Merck). Reactions were monitored by thin-layer
chromatography (TLC) on silica gel plates containing a fluorescent
indicator (Merck Silica Gel 60 F254) and spots were detected
under UV light (254 nm) and hydroxamic acids were visualised
with FeCl3 aqueous solution. Evaporation was carried in vacuo
(rotating evaporator). Sodium sulphate was always used as the
drying agent. Commercially available chemicals were purchased
from Sigma-Aldrich. The oxime 5d is commercially available and
was purchased from Sigma-Aldrich. Elemental analysis was used
to determine the purity of target compounds and was performed
by our analytical laboratory and agreed with the theoretical values
to within ±0.4%.

A solution of the appropriate commercially available aldehyde or
ketone (3.21 mmol) and NH2OH.HCl (6 mmol) in a mixture of EtOH
98% (5.3 ml) and Pyridine (8.3 mmol) was stirred at 150  C for
150 min. Then, the solvent was evaporated and the crude was
added with a saturated solution of NaHCO3, filtered and washed
with water to obtain the oximes 5a–c,e,f.

4.2.1. (E)-4-(methylthio)benzaldehyde oxime (5a)
The title compound was prepared from the appropriate aldehyde
following the general procedure to obtain 5a as a white solid
(64% yield). 1HNMR (CDCl3):8.03 (s, 1H); 7.52–7.48 and 7.25–7.21
(m, 4H, J ¼ 8.42 Hz), 2.51 (s, 3H).
4.2.2. (E)-1,10 -biphenyl-4-carbaldehyde oxime (5b)
The title compound was prepared from the appropriate aldehyde
following the general procedure to obtain 5b as a white solid
(99% yield). 1H NMR (200 MHz, CDCl3) d: 8.19 (s, 1H); 7.88–7.83
and 7.55–7.47 (m, 8H);

4.2.3. (E)-2-naphthaldehyde oxime (5c)
The title compound was prepared from the appropriate aldehyde
following the general procedure to obtain 5c as a white solid
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(64% yield). 1H NMR (200 MHz, CDCl3) d: 8.30 (s, 1H); 7.88–7.83
and 7.55–7.47 (m, 8H).

4.2.4. 1-([1,10 -Biphenyl]-4-yl)ethanone oxime(5e)
The title compound was prepared from the appropriate ketone
following the general procedure to obtain 5e as a white solid
(96% yield). 1H NMR (200 MHz, CDCl3) d: 7.74–7.59 (m, 6H);
7.49–7.34 (m, 3H); 2,33 (s, 3H).

4.2.5. 1-([1,10 -Biphenyl]-4-yl)ethanone oxime(5f)
The title compound was prepared from the appropriate aldehyde
following the general procedure to obtain 5f as a white solid
(90% yield). 1H NMR (200 MHz, CDCl3) d: 8.43 (s, 1H), 8.18–8.09 (m,
3H), 7.97–7.93 (m, 1H), 7.84–7.70 (m, 1H), 7.60–7.52 (m,1H).

4.3. General procedure for the synthesis of ethyl
(E)–3–((arylideneamino)oxy)propanoates 6a–c
To a solution of the appropriate oxime 5a–c (3.36 mmol) in MeCN
(1.5 ml), triphenylphosphine (0.67 mmol) and ethyl acrylate
(3.36 mmol) were added. The obtained solution was stirred at
65  C for 72 h. The reaction mixture was dried under reduced pressure to give a crude oil that was purified by flash chromatography
on silica gel. The evaporation of the selected fractions gave a
pure yellow oil constituted exclusively by the E isomer.

4.3.1. Ethyl (E)-3-(((4-(methylthio)benzylidene)amino)oxy)propanoate (6a)
The title compound was prepared from the oxime 5a following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 7:3) to give a yellow oil (30% yield). 1H NMR (200 MHz, CDCl3) d: 8.03 (s, 1H),
7.51–7.47 (m, 2H), 7.28–7.21 (m, 2H), 4.44 (t, J ¼ 6.41 Hz, 2H), 4.19
(q, J ¼ 7.14 Hz, 2H), 2.75 (t, J ¼ 6.41 Hz, 2H), 2.51 (s, 3H), 1.28 (t,
J ¼ 7.14 Hz, 3H).

4.4. General procedure for the synthesis of ethyl
(E)–4–((arylideneamino)oxy)pentanoates (7a–f)
To a cooled (0  C) and stirred solution of the appropriate oxime
5a–f (4.69 mmol) and ethyl 5-bromopentanoate (3.91 mmol) in
anhydrous DMF (25 ml), Cs2CO3 (4.69 mmol) was added. The
resulting mixture was stirred for 24 h at room temperature. Then,
water was added and the solution was extracted with Et2O. The
organic phases were combined, dried with Na2SO4, filtered, and
evaporated under vacuum. The crude was purified affording exclusively the E isomer.
4.4.1. Ethyl (E)-5-(((4-(methylthio)benzylidene)amino)oxy)pentanoate (7a)
The title compound was prepared from the oxime 5a following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 6:4) to give a yellow oil (48% yield). 1H NMR (200 MHz, CDCl3) d: 8.03 (s, 1H), 7.23
(m, 2H), 7.50 (m, 2H), 4.09–4.21 (m, 4H), 2.51 (s, 3H), 2.41–2.32 (m,
2H), 1.77–1.80 (m, 4H),1.26 (t, J ¼ 7.14 Hz, 3H).
4.4.2. Ethyl (E)-5-((([1,10 -biphenyl]-4-ylmethylene)amino)oxy)pentanoate (7b)
The title compound was prepared from the oxime 5b following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 7:3) to give a yellow oil (85% yield). 1H NMR (200 MHz, CDCl3) d: 8.01 (s, 1H),
7.74–7.59(m, 6H), 7.48–7.32 (m, 3H) 4.25–4.17 (m, 2H), 4.21 (q,
J ¼ 7.14 Hz, 2H), 2.37–2.34 (m, 2H), 1.80–1.74 (m, 4H), 1.26 (t,
J ¼ 7.14 Hz, 3H).
4.4.3. Ethyl (E)-5-(((naphthalen-2-ylmethylene)amino)oxy)pentanoate (7c)
The title compound was prepared from the oxime 5c following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 6:4) to give a yellow oil (65% yield). 1H NMR (200 MHz, CDCl3) d: 8.22 (s, 1H),
7.85–7.78 (m, 5H), 7.53–7.47 (m, 2H), 4.25–4.20 (m, 2H), 4.18–4.08
(q, J ¼ 7.14 Hz, 2H), 2.41–2.35 (m, 2H), 1.82–1.75 (m, 4H), 1.25 (t,
J ¼ 7.14 Hz, 3H).

4.3.2. Ethyl (E)-3-((([1,10 -biphenyl]-4-ylmethylene)amino)oxy)propanoate (6b)
The title compound was prepared from the oxime 5b following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 7:3) to give a yellow oil (35% yield). 1H NMR (200 MHz, CDCl3) d: 8.11 (s, 1H),
7.49–7.39 (m, 3H), 7.64–7.57 (m, 6H), 4.46 (t, J ¼ 6.41 Hz, 2H), 4.19
(q, J ¼ 7.14 Hz, 2H), 2.76 (t, J ¼ 6.41 Hz, 2H), 1.27 (t, J ¼ 7.14 Hz, 3H).

4.4.4. Ethyl (E)-4-((benzylideneamino)oxypentanoate (7d)
The title compound was prepared from the oxime 5d following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 6:4) to give a yellow oil (80% yield). 1H NMR (200 MHz, CDCl3) 8.07 (s,1H),
7.59–7.55(m, 2H), 7.37–7.35 (m, 3H), 4.21–4.14 (m, 2H), 4.12 (q,
J ¼ 7.14 Hz, 2H), 2.40–2.33 (m, 2H), 1.79–1.72 (m, 4H), 1.25 (t,
J ¼ 7.14 Hz, 3H),

4.3.3. Ethyl (E)-3-(((naphthalen-2-ylmethylene)amino)oxy)propanoate (6c)
The title compound was prepared from the oxime 5b following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 9:1) to give a yellow oil (42% yield). 1H NMR (200 MHz, CDCl3) d: 8.21 (s, 1H),
7.84–7.82 (m, 5H), 7.52–7.47 (m, 2H), 4.49 (t, J ¼ 6.41 Hz, 2H), 4.18
(q, J ¼ 7.14 Hz, 2H), 2.77 (t, J ¼ 6.41 Hz, 2H), 1.27 (t, J ¼ 7.14 Hz, 3H),

4.4.5. Ethyl (E)-4-(((1-([1,10 -biphenyl]-4-yl)ethylidene)amino)oxy)butanoate (7e)
The title compound was prepared from the oxime 5e following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 6:4) to give a yellow oil (66% yield). 1H NMR (200 MHz, CDCl3) d: 8.02 (s, 1H),
7.74–7.59 (m, 6H), 7.48–7.32 (m, 3H), 4.25–4.20 (m, 2H), 4.21 (q,
J ¼ 7.14 Hz, 2H), 2.41–2.30 (m, 2H), 2.26 (s, 3H), 1.94–1.78 (m, 4H),
1.26 (t, J ¼ 7.14 Hz, 3H).
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4.4.6.
Ethyl
(E)-4-(((quinolin-3-ylmethylene)amino)oxy)butanoate (7f)
The title compound was prepared from the oxime 5e following
the general procedure. The crude product was purified by flash
chromatography on silica gel (n-hexane/EtOAc 7:3) to give a yellow oil (90% yield). 1H NMR (200 MHz, CDCl3) d: 8.30 (s, 1H),
8.14–7.94 (m,3H), 7.82–7.66 (m, 2H), 7.57–7.49 (m, 1H), 4.27 (m,
2H), 4.12 (q, J ¼ 7.14 Hz, 2H), 2.40–2.32 (m, 2H), 1.80–1.72 (m, 4H),
1.24 (t, J ¼ 7.14 Hz, 3H).
4.5. General procedure for the synthesis of
(E)–N–hydroxy–3–((arylideneamino)oxy)propanamides (1a–c)
To a stirred solution of KOH (1.32 mmol) in MeOH (2 ml) was
added a 50% aqueous solution of NH2OH (0.089 ml). This solution
was added dropwise in 30 min to a stirred and cooled solution
(0  C) of the appropriate ethyl ester 6a2c (0.087 mmol) in
MeOH (2 ml).
After stirring at 0  C for 30 min. and at room temperature overnight the mixture was evaporated in vacuo. The residue was
added with water and the aqueous solution washed with Et2O.
The aqueous phase was acidified with 10% HCl to pH ¼ 5 and
then extracted with EtOAc. Organic layers were collected, dried,
and evaporated in vacuo to give a solid.
4.5.1.
(E)-N-hydroxy-3-(((4-(methylthio)benzylidene)amino)oxy)
propanamide(1a)
The title compound was prepared from the ethyl ester 6a following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
semisolid (40% yield). 1H NMR (400 MHz, DMSO-d6): d 10.48 (bs,
1H), 8.81 (bs, 1H), 8.11 (s, 1H), 7.55–7.53 (m, 2H), 7.33–7.28 (m,
2H); 4.35 (t, J ¼ 6 Hz, 2H), 2.50 (s, 3H), 2.41 (t, J ¼ 6 Hz, 2H). 13C
(100 MHz, DMSO-d6): d 167.1, 148.5, 141.0, 128.9, 128.4, 127.7,
126.2, 70.3, 32.9, 14.8. Elemental analysis calcd. (%) for
C11H14N2O3S: C 51.95; H 5.55; N 11.02; found: C 52.02, H 5.61,
N 11.25.
4.5.2. (E)-3-((([1,10 -biphenyl]-4-ylmethylene)amino)oxy)-N-hydroxypropanamide (1b)
The title compound was prepared from the ethyl ester 6b following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
yellow solid. (40% yield). M.p. ¼ 128–130  C. 1H NMR (400 MHz,
DMSO-d6) d: 10.47 (s, 1H), 8.79 (s, 1H), 8.26 (s, 1H),7.76–7.69 (m,
6H, Ar), 7.57–7.46 (m, 2H, Ar), 7.41–7.38 (m, 1H, Ar), 4.32 (t,
J ¼ 6.4 Hz, 2H), 2.39 (t, J ¼ 6.4 Hz, 2H). 13C NMR (100 MHz, DMSOd6): d 167.0, 149.1, 141.9, 139.8, 131.9, 129.5, 128.3, 127.9, 127.5,
127.1, 70.3, 33.0. Elemental analysis calcd. (%) for C16H16N2O3: C,
67.59; H, 5.67; N, 9.85; found: C, 69.99, H, 6.02, N, 10.02.

4.5.3. (E)-N-hydroxy-3-(((naphthalen-2-ylmethylene)amino)oxy)propanamide (1c)
The title compound was prepared from the ethyl ester 6c following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
yellow solid. (47% yield). M.p. ¼ 153–155  C; 1HNMR (400 MHz,
DMSO-d6) d: 10.48 (bs, 1H), 8.80 (s,1H), 8.35 (s, 1H), 8.07 (s, 1H),
7.95–7.93 (m, 3H), 7.81 (m, 1H), 7.57–7.55 (m, 2H), 4.35 (t,
J ¼ 6.24 Hz, 2H), 2.41 (t, J ¼ 6.24 Hz, 2H). 13C NMR (100 MHz, DMSO-
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d6) d: 167.1, 149.4, 134.0, 133.2, 130.1, 128.9, 128.8, 128.7, 128.2,
127.6, 127.3, 127.1, 70.3, 33.0, 14.9. Elemental analysis calcd. (%)
for C14H14N2O3: C, 65.11; H, 5.46; N, 10.85; found: C, 65.19, H, 5.52,
N, 10.92.
4.6. General procedure for the synthesis of
(E)–3–((arylideneamino)oxy)pentananamide (2a–f)
To a stirred solution of KOH (2.47 mmol) in MeOH (4 ml) was
added a 50% aqueous solution of NH2OH (0.49 ml). This solution
was added dropwise in 30 min to a stirred and cooled solution
(0  C) of the appropriate ethyl ester 7a2f (3.12 mmol) in
MeOH (2 ml).
After stirring at 0  C for 30 min. and at room temperature overnight the mixture evaporated in vacuo. The residue was added
with water and the aqueous solution washed with Et2O. Aqueous
phase was acidified with 10% HCl to pH ¼ 5 and then extracted
with EtOAc. Organic layers were collected, dried, and evaporated
in vacuo to give a crude solid.
4.6.1. (E)-N-hydroxy-5-(((4-(methylthio)benzylidene)amino)oxy)pentanamide (2a)
The title compound was prepared from the ethyl ester 7a following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
yellow semisolid. (45% yield); 1H NMR (400 MHz, DMSO-d6): d
10.48 (bs, 1H), 8.81 (bs, 1H), 8.18 (s, 1H), 7.55–7.53 (m, 2H),
7.33–7.28 (m, 2H); 4.09 (t, J ¼ 6 Hz, 2H), 2.62 (t, J ¼ 6 Hz, 2H), 2.50
(s, 3H), 1.68–1.57 (m, 4H). 13C (100 MHz, DMSO-d6): d 167.1, 148.5,
141.0, 128.9, 128.4, 127.7, 126.2, 70.3, 32.9, 28.2, 21.6. Elemental
analysis calcd. (%) for C13H18N2O3S: C, 55.30; H, 6.43; N, 9.92;
found: C, 55.39, H, 6.52, N, 10.02.
4.6.2. (E)-5-((([1,10 -biphenyl]-4-ylmethylene)amino)oxy)-N-hydroxypentanamide (2b) (SN2)
The title compound was prepared from the ethyl ester 7b following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
yellow solid (35% yield). M.p. ¼160–162  C. 1HNMR (400 MHz,
DMSO-d6): d 8.27 (s, 1H),7.73–7.69 (m, 6H, Ar), 7.50–7.46 (m, 2H,
Ar), 7.40–7.38 (m, 1H, Ar), 4.10 (m, 2H), 1.84 (t, J ¼ 7.1 Hz, 2H),
1.64–1.47 (m, 4H). 13C NMR (100 MHz, DMSO-d6): d 175.5, 148.27,
141.7, 139.8, 131.8, 129.4, 128.3, 127.9, 127.5, 127.1, 74.5, 29.6,
23.5. Elemental analysis calcd. (%) for C18H20N2O3: C, 69.21; H,
6.45; N, 8.97; found: C, 69.33, H, 6.52, N, 9.02.

4.6.3. (E)-N-hydroxy-5-(((naphthalen-2-ylmethylene)amino)oxy)pentanamide (2c) (LD10)
The title compound was prepared from the ethyl ester 7c following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
yellow solid. (35% yield). M.p. ¼ 229–231  C. 1HNMR (400 MHz,
DMSO-d6) d: 10.53 (bs, 1H), 8.81 (bs, 1H), 8.37 (s, 1H), 8.06 (s, 1H),
7.95–7.92 (m, 3H), 7.83–7.81 (m, 1H), 7.57–7.54 (m, 2H), 4.13 (t,
J ¼ 6.8 Hz, 2H), 1.88 (t, J ¼ 7.2 Hz, 2H), 1.67–1.50 (m, 4H). 13C NMR
(100 MHz, DMSO-d6) d: 175.6, 148.9, 134.0, 133.3, 130.4, 128.9,
128.7, 128.5, 128.2, 127.5, 127.2, 123.1, 74.5, 38.9, 29.6, 23.4.
Elemental analysis calcd. (%) for C16H18N2O3: C, 67.12; H, 6.34; N,
9.78; found: C, 67.33, H, 6.42, N, 9.82.
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4.6.4. (E)-5-((benzylideneamino)oxy)-N-hydroxypentanamide (2d)
The title compound was prepared from the ethyl ester 7d following the general procedure. The crude product was purified by
flash chromatography on silica gel (n-hexane/EtOAc 3:7) to give a
yellow solid. (35% yield). M.p. ¼ 134–136  C. 1HNMR (400 MHz,
DMSO-d6): d 10.51 (bs, 1H), 8.81 (bs, 1H), 8.22–8.21 (m, 1H, Ar),
7.61–7.59 (m, 2H, Ar), 7.41–7.39 (m, 2H, Ar), 4.11–4.05 (m, 2H),
1.65–1.46 (m, 4H). 13C NMR (100 MHz, DMSO-d6): d 172.2, 148.8,
132.6, 130.2, 129.2, 127.2, 73.7, 35.6, 28.7, 23.3. Elemental analysis
calcd. (%) for C12H16N2O3: C, 61.00; H, 6.83; N, 11.86; found: C,
61.13, H, 6.92, N, 11.92.
4.6.5.
(E)-5-(((1-([1,10 -biphenyl]-4-yl)ethylidene)amino)oxy)-Nhydroxypentanamide (2e) (VS16)
The title compound was prepared from the ethyl ester 7e following the general procedure. The crude product was purified by trituration with Et2O to give a white solid (35% yield). M.p. ¼ 142  C;
1
HNMR (400 MHz, DMSO-d6) d: 10.72 (s, 1H), 9.39 (bs,
1H),7.76–7.68 (m, 6H, Ar), 7.50–7.46 (m, 2H, Ar), 7.40–7.38 (m, 1H,
Ar), 4.13 (t, J ¼ 6.0 Hz, 2H), 3.40–3.28 (m, 2H), 2.12 (s, 3H), 1.90 (t,
J ¼ 7.1 Hz, 2H), 1.64–1.55 (m, 4H). 13C NMR (100 MHz, DMSO-d6): d
168.4, 153.7, 141.1, 139.9, 135.6, 129.4, 128.2, 127.1, 126.8, 73.9,
33.2, 29.1, 22.8, 12.7. Elemental analysis calcd. (%) for C19H22N2O3:
C, 69.92; H, 6.79; N, 8.58; found: C, 69.93, H, 6.82, N, 8.63.

4.6.6. (E)-N-hydroxy-5-(((quinolin-3-ylmethylene)amino)oxy)pentanamide (2f) (VS13)
The title compound was prepared from the ethyl ester 7f following the general procedure. The crude product was purified by
crystallisation with CHCl3 to give a white solid (42% yield). M.p. ¼
113  C; 1HNMR (400 MHz, DMSO-d6) d: 10.37 (bs, 1H), 8.68 (s,1H),
8.39 (m, 1H) 8.31 (s, 1H), 8.02 (m, 2H), 7.93 (m, 1H), 7.80 (m, 1H),
7.65 (m, 1H), 4.22 (t, J ¼ 6.28 Hz, 2H), 2.01 (t, J ¼ 7.2 Hz, 2H),
1.71–1.61 (m, 4H). 13C NMR (100 MHz, DMSO-d6): d 169.3, 152.1,
149.9, 147.8, 137.3, 130.6, 129.3, 128.5, 128.3, 127.8, 118.1, 74.5,
32.4, 28.6, 22.1. Elemental analysis calcd. (%) for C15H17N3O3: C,
62.71; H, 5.96; N, 14.63; found: C, 62.73, H, 6.02, N, 14.69.
4.7. General procedure for the synthesis of
(E)–3–((arylideneamino)oxy)propanoic acids (3a–c) and
(E)–3–((arylideneamino)oxy)pentanoic acids (4a–e)

14.7. Elemental analysis calcd. (%) for C11H13NO3S: C, 55.21; H,
5.48; N, 5.85; found: C, 55.23, H, 5.52, N, 5.89.
4.7.2.
(E)-3-((([1,10 -biphenyl]-4-ylmethylene)amino)oxy)propanoic
acid (3b)
The title compound was prepared from the ethyl ester 6b following the general procedure white solid (48% yield). M.p. ¼
104–106  C. 1HNMR (400 MHz, DMSO-d6): d 8.28 (s, 1H), 7.74–7.69
(m, 6H, Ar), 7.50–7.46 (m, 2H, Ar), 7.41–7.38 (m, 1H, Ar), 4.32 (t,
J ¼ 6.4 Hz, 2H), 2.63 (t, J ¼ 7.1 Hz, 2H), 13C NMR (100 MHz, DMSOd6): d 172.8, 149.1, 142.0, 139.8, 131.5, 129.5, 128.3, 127.9, 127.5,
127.13, 70.1, 34.7. Elemental analysis calcd. (%) for C16H15NO3: C,
71.36; H, 5.61; N, 5.20; found: C, 71.43, H, 5.62, N, 5.29.

4.7.3.
(E)-3-(((naphthalen-2-ylmethylene)amino)oxy)propanoic
acid (3c)
The title compound was prepared from the ethyl ester 6c following the general procedure white semisolid (56% yield). 1HNMR
(400 MHz, DMSO-d6): d 12.48 (bs, 1H), 8.38 (s, 1H), 8.06 (s, 1H, Ar),
7.96–7.92 (m, 3H, Ar), 7.81 (m, 1H, Ar), 7.57–7.55 (m, 2H, Ar), 4.35
(t, J ¼ 6.00 Hz, 2H), 2.66 (t, J ¼ 6.20 Hz, 2H).13C NMR (100 MHz,
DMSO-d6): d 173.1, 149.5, 134.0, 133.2, 130.1, 128.9, 128.8, 128.7,
128.2, 127.6, 127.3, 123.1, 70.1, 35.3. Elemental analysis calcd. (%)
for C14H13NO3: C, 69.12; H, 5.39; N, 5.76; found: C, 69.13, H, 5.42,
N, 5.79.

4.7.4.
(E)-5-(((4-(methylthio)benzylidene)amino)oxy)pentanoic
acid (4a)
The title compound was prepared from the ethyl ester 7a following the general procedure white solid (76% yield). M.p. ¼
70–72  C; 1HNMR (400 MHz, DMSO-d6): d 12.10 (bs, 1H), 8.19 (s,
1H), 7.54 (m, 2H, Ar), 7.31 (m, 2H, Ar), 4.09 (t, J ¼ 6.00 Hz, 2H), 2.51
(s, 3H), 2.26 (t, J ¼ 7.2 Hz, 2H), 1.68–1.63 (m, 4H). 13C NMR
(100 MHz, DMSO-d6): d 174.8, 148.5, 141.0, 128.9, 128.4, 127.6,
126.1, 73.6, 33.8, 28.6, 21.6, 14.7. Elemental analysis calcd. (%) for
C13H17NO3S: C, 58.40; H, 6.41; N, 5.24; found: C, 58.55, H, 6.42,
N, 5.29.

A solution of the appropriate ethyl ester 6a–c, 7a–d (1.35 mmol)
in anhydrous EtOH (0.21 ml) was added with a solution of 2 N
KOH in anhydrous EtOH (4.90 ml). The resulting mixture was
stirred at 40  C for 24 h. Ethanol was evaporated and the solid
residue was dissolved in water and washed with Et2O. Aqueous
basic phase was then acidified with 1 N HCl until pH ¼ 5 was
obtained, and the product was extracted with EtOAc. Organic
layers were collected, dried, evaporated to dryness.

4.7.5.
(E)-5-((([1,10 -biphenyl]-4-ylmethylene)amino)oxy)pentanoic
acid (4b)
The title compound was prepared from the ethyl ester 7b following the general procedure white solid (64% yield). M.p. ¼
98–100  C; 1HNMR (400 MHz, DMSO-d6): d 12.02 (bs, 1H),8.28 (s,
1H), 7.74–7.68 (m, 6H, Ar), 7.50–7.46 (m, 2H, Ar), 7.40–7.38 (m, 1H,
Ar), 4.13 (t, J ¼ 6.4 2H), 2.27 (t, J ¼ 7.2 Hz, 2H), 1.70–1.58 (m, 4H).
13
C NMR (100 MHz, DMSO-d6): d 174.8, 148.6, 141.8, 139.8, 131.6,
129.5, 128.3, 127.8, 127.5, 127.1, 73.7, 33.8, 28.6, 21.6. Elemental
analysis calcd. (%) for C18H19NO3: C, 72.71; H, 6.44; N, 4.71; found:
C, 72.73, H, 6.46, N, 4.79.

4.7.1.
(E)-3-(((4-(methylthio)benzylidene)amino)oxy)propanoic
acid (3a)
The title compound was prepared from the ethyl ester 6a following the general procedure white solid (45% yield). M.p. ¼
76–78  C. 1HNMR (400 MHz, DMSO-d6): d 12.28 (bs, 1H), 8.17 (s,
1H), 7.53 (m, 2H, Ar), 7.28 (m, 2H, Ar), 4.28 (t, J ¼ 6.24 Hz, 2H), 2.60
(t, J ¼ 6.24 Hz, 2H), 2.51 (s, 3H).13C NMR (100 MHz, DMSO-d6): d
172.8, 149.0, 141.2, 130.1, 128.7, 127.7, 126.1, 125.3, 70.0, 34.7,

4.7.6.
(E)-5-(((naphthalen-2-ylmethylene)amino)oxy)pentanoic
acid (4c)
The title compound was prepared from the ethyl ester 7c following the general procedure. Orange solid (55% yield). M.p. ¼
68–70  C; 1HNMR (400 MHz, DMSO-d6) d: 12.01 (bs, 1H), 8.38 (s,
1H), 8.06 (s, 1H, Ar), 7.96–7.92 (m, 3H, Ar), 7.81 (m, 1H, Ar),
7.57–7.54 (m, 2H, Ar), 4.16 (t, J ¼ 6.4 Hz, 2H), 2.28 (t, J ¼ 7.2 Hz, 2H).
13
C NMR (100 MHz, DMSO-d6): d 174.8, 149.0, 134.0, 133.2, 130.2,
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128.9, 128.7, 128.6, 128.2, 127.5, 127.2, 123.1, 73.8, 33.9, 28.6, 21.6.
Elemental analysis calcd. (%) for C16H17NO3: C, 70.83; H, 6.32; N,
5.16; found: C, 70.93, H, 6.36, N, 5.19.

4.7.7. (E)-5-((benzylideneamino)oxy)pentanoic acid (4d)
The title compound was prepared from the ethyl ester 7d following the general procedure. Colourless oil (47% yield). 1H NMR
(400 MHz, DMSO-d6): d 12.03 (bs, 1H), 8.23 (s, 1H), 7.61–7.59 (m,
2H), 7.42–7.39 (m, 3H); 4.10 (t, J ¼ 6 Hz, 2H), 2.26 (t, J ¼ 6 Hz, 2H),
1.68–1.55 (m, 4H). 13C (100 MHz, DMSO-d6): d 175.3, 149.4, 133.0,
130.7, 129.7, 127.7, 74.1, 34.3, 29.2, 22.0. Elemental analysis calcd.
(%) for C12H15NO3: C, 65.14; H, 6.83; N, 6.33; found: C, 65.23, H,
6.86, N, 6.39.
4.7.8.
(E)-5-(((1-([1,10 -biphenyl]-4-yl)ethylidene)amino)oxy)pentanoic acid (4e)
The title compound was prepared from the ethyl ester 7e following the general procedure. White solid (33% yield). M.p. ¼
137–139  C; 1HNMR (400 MHz, DMSO-d6) d: 7.78–7.67 (m, 6H),
7.52–7.37 (m, 3H), 4.11 (t, 2H, J ¼ 6.0 Hz), 2.21 (s, 3H), 1.83 (t, 2H,
J ¼ 7.3 Hz), 1.64–1.60 (m, 2H), 1.52–1.45 (m, 2H). 13C NMR
(100 MHz, DMSO-d6): d 175.5, 153.5, 141.0, 139.9, 135.7, 129.5,
128.2, 127.1, 126.8, 79.6, 74.4, 29.8, 23.6, 12.7. Elemental analysis
calcd. (%) for C19H21NO3: C, 73.29; H, 6.80; N, 4.50; found: C, 73.33,
H, 6.86, N, 4.59.
4.8. HDACs inhibition assays
HDAC inhibitory activity of newly synthesised compounds was
evaluated using an HDAC Fluorimetric Assay/Drug Discovery Kit
(AK-500, BIOMOL). Briefly, HeLa nuclear extract (0.5 ml/well) was
added to each well already containing the assay buffer (control),
diluted trichostatin A (standard reference), or various concentrations of HDAC inhibitors and were incubated at 37  C with 25 mM
of Fluor de LysTM Substrate. Reactions were stopped after 30 min
by adding Fluor de LysTM Developer. After the addition of this
developer, the plate was incubated at room temperature for
15 min, the fluorescence intensity of the wells was measured on a
fluorometric plate reader with excitation set at 360 nm and emission detection set at 460 nm.
4.9. Microfluidic chip–based HDAC inhibition assay
Test compounds were screened against human histone deacetylases (HDACs) 1, 3, 6, and 8 using the Calliper off-chip mobility
shift assay technology. All HDACs were purchased from BPS
Bioscience and four selective substrates were used according to
the targeted isozyme. A (FAM)-labelled Substrate A peptide (purchasable from PerkinElmer, Product Number CLS96000) was synthesised in-house as previously reported34 and used for HDAC1
assays. The other three substrates were purchased from
PerkinElmer: two (FITC)-labelled peptides (p53 Acetylated Peptide
and Histone 4 Acetylated Peptide, Product Number 760512 and
760513 respectively) were used for HDAC 3 and 6 assays, respectively; a (FAM)-labelled peptide (Broad Substrate B, Product
Number CLS960007) was employed as a substrate for HDAC8. Test
and standard compounds (3-fold serial dilution starting at 30 mM,
10 concentrations) were incubated with purified HDACs and 1 mM
of substrate for 60 min at room temperature in an assay buffer
composed of 25 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2.7 mM KCl,
1 mM MgCl2, and 0.01% BSA. Reactions were performed in
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duplicate and terminated by the addition of a stop buffer containing 100 mM HEPES, 0.015% Brij-35, 10 mM EDTA, 0.1% CR-3, and
1.5 mM of the pan-HDAC inhibitor Panobinostat. A DMSO concentration of 3.33% characterised both compounds’ titration and controls wells. Buffers components, except for CR-3 (LabChip Coating
Reagent 3, purchased from PerkinElmer, Product Number 760050)
and
Panobinostat
(LBH589,
purchased
from
ApexBio
Technology)35,36 were purchased from Sigma Aldrich. As standard
compounds (positive controls), three well-known HDAC inhibitors
were used: Entinostat (MS-275)37, SAHA38, and Tubastatin A39 (all
purchased from Selleck Chemicals). In the case of SAHA an additional 15-point dose curve screening was performed over HDACs
3 and 6. Fluorescence intensity of electrophoretically separated
substrate and the product was detected using the LabChip EZ
Reader and the inhibition percentage values were normalised
according to the associated 0% and 100% inhibition control wells.
The data were then analysed by non-linear regression using
GraphPad Prism 6.01 software40 to derive IC50 values.
4.10. Molecular modelling
Crystal structures of human HDAC1, HDAC3, HDAC6, and HDAC8
(codes: 5ICN41, 4A6942, 5EDU43, and 3F0744) were downloaded
from Protein Data Bank (PDB) and superposed for aligning their
coordinates using Chimaera45. Docking of LD10, VS13, VS16, and
SN2 was carried out using the same procedure identified as the
best through preliminary cross- and re-docking studies, by means
of ASP fitness function of GOLD software46. A scaffold match constraint on the hydroxamate position deduced from the crystallographic ligand structures, with a default strength of 5, was
applied. The region of interest for docking was defined in GOLD
in such a manner that every protein contained all the residues
within 10 Å from the superposed co-crystallised ligands. The “allow
early termination” command was deactivated. All ligands were
submitted to 80 Genetic Algorithm runs, clustering the output orientations using an RMSD cut-off of 1.5 Å. The metal coordination
of the zinc ion was set in an octahedral geometry, as in the crystallographic structures. The default GOLD parameters were used
for all other settings.
The ligands were built using Maestro47 and then subjected,
after a minimisation step, to a conformational search of 1,000
steps in a water environment (using the generalized-Born/surfacearea model) by means of Macromodel48 software. The algorithm
used was the Monte Carlo method with the MMFFs force field
and a distance-dependent dielectric constant of 1.0. Missing
hydrogens were added to the protein according to the predicted
protonation state at the physiological pH, 7.0. Asn and Gln residues were absent in the range of interest for the direct contacts
of docking; flip corrections were necessary only for the histidines
involved in the zinc coordination, which were protonated in such
a way to expose the lone pair towards the zinc atom.
4.11. Cells and cell treatments
The human UM cell lines 92.149 and Mel27050 (kindly provided to
RG by M. J. Jager) and the ovarian cancer cell lines SKOV3 (ATTC),
A2780 (ICLC) and A2774 (IST Genoa) were grown in RPMI 1640,
with 2 mM L-glutamine, 10% heat-inactivated foetal calf serum,
and 100 lg/ml penicillin-streptomycin (Lonza) at 37  C in a 5%
CO2 incubator. The cells were cultured for no longer than
3 months, when an aliquot of the original stock was thawed,
which had been genotyped using the Cell IDTM System (Promega,
G9500) and the GeneMapperV software, version 4.0.
R
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Table 3. QRT-PCR primers.
Gene
GAPDH
POLR2A
RAD54L
RAD51
CLU (TRPM2)
DHRS2 (Hep27)
CDKN1A (P21)

Forward primer

Reverse primer

GAAGGTGAAGGTCGGAGT
GACAATGCAGAGAAGCTGG
CCCTTTCTTCCATCACCTCGCT
TCTCTGGCAGTGATGTCCTGGA
TGCGGATGAAGGACCAGTGTGA
GGTGCTGTCATCCTGGTCTCTT
AGGTGGACCTGGAGACTCTCAG

CATGGGTGGAATCATATTGGAA
GCAGGAAGACATCATCATCC
GCCTTAGAGCTGTAACCAGGAG
TAAAGGGCGGTGGCACTGTCTA
TTTCCTGGTCAACCTCTCAGCG
CCAGCTCCAATGCCAGTGTTCT
TCCTCTTGGAGAAGATCAGCCG

Treatments with the compounds were performed with slight
differences, according to the final use of the samples. For the cell
viability assay with MTT, cells were seeded in 96-well flat-bottom
plates in culture medium at 5  103 cells/well, whereas for cell
cycle analysis and QRT-PCR cells were seeded in 24-well plates at
5  104 cells/well. The day after, a culture medium containing the
appropriate amount of compounds or their solvent control DMSO
was added, and treatments were carried out for the indicated time.
4.12. Evaluation of cell viability and cell cycle status
Cell viability after treatment was evaluated by a microculture
tetrazolium reduction assay using MTT [3–(4,5-dimethyltiazol-2-yl)
2,5-diphenyltetrazolium bromide; Sigma]. At 72 h of treatment,
20 ll of MTT stock solution (2 mg/ml in PBS) were added to 200 ll
cell cultures for an additional 4 h of incubation. MTT-containing
culture medium was then removed and precipitated formazan
was dissolved in 100 ll of DMSO. Results were read within 15 min
in a microplate reader spectrometer at 540 nm (MEDGENIX 400
ATC, Medgenix Diagnostics), and the means of quadruplicates
were calculated. Cell survival was expressed as a percentage of
control samples.
To assess the cell cycle status of treated samples, after 48 h of
incubation the cells were harvested, washed twice with cold PBS,
and fixed in 70% ethyl alcohol at 20  C overnight. The day after,
the samples were washed with cold PBS and incubated for 20 min
with propidium iodide (PI) staining solution (50 lg/ml PI, 0.05%
Triton X-100, 0.2 mg/ml RNase A in PBS) at room temperature.
Flow cytometric analysis of DNA content was performed using a
FACScan flow cytometer with the CellQuest software (BD
Biosciences). Gating on viable cells was performed using physical
parameters and 104 gated events were acquired. Cell cycle analysis on the gated PI distribution was performed using
Modfit software.
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